首页> 美国卫生研究院文献>Frontiers in Pharmacology >Therapeutic Value of Voltage-Gated Sodium Channel Inhibitors in Breast Colorectal and Prostate Cancer: A Systematic Review
【2h】

Therapeutic Value of Voltage-Gated Sodium Channel Inhibitors in Breast Colorectal and Prostate Cancer: A Systematic Review

机译:电压门控钠通道抑制剂在乳腺癌结直肠癌和前列腺癌中的治疗价值:系统评价

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Although survival rates of breast, colon, and prostate cancers are improving, deaths from these tumors frequently occur due to metastasis. Voltage-gated Na+ channels (VGSCs) are membrane proteins, which regulate membrane current and cellular migration during nervous system organogenesis. VGSCs are also expressed in fibroblasts, immune cells, glia, and metastatic cancer cells. VGSCs regulate migration and invasion of breast, bowel, and prostate cancer cells, suggesting that they may be novel anti-metastatic targets. We conducted a systematic review of clinical and preclinical studies testing the effects of VGSC-inhibiting drugs in cancer. Two-hundred and four publications were identified, of which two human, two mouse, and 20 in vitro publications were included. In the clinical studies, the effect of these drugs on survival and metastatic relapse is not clear. The 22 preclinical studies collectively suggest that several VGSC-inhibiting drugs inhibit cancer proliferation, migration, and invasion. None of the human and only six of the preclinical studies directly investigated the effect of the drugs on VGSC activity. Studies were difficult to compare due to lack of standardized methodology and outcome measures. We conclude that the benefits of VGSC inhibitors require further investigation. Standardization of future studies and outcome measures should enable meaningful study comparisons.
机译:尽管乳腺癌,结肠癌和前列腺癌的存活率正在提高,但是由于转移,这些肿瘤的死亡经常发生。电压门控Na + 通道(VGSCs)是膜蛋白,在神经系统器官发生过程中调节膜电流和细胞迁移。 VGSC还在成纤维细胞,免疫细胞,神经胶质细胞和转移性癌细胞中表达。 VGSCs调节乳腺癌,肠癌和前列腺癌细胞的迁移和侵袭,表明它们可能是新型的抗转移靶标。我们对临床和临床前研究进行了系统的综述,以测试抑制VGSC的药物在癌症中的作用。确定了200种出版物,其中包括2篇人类,2篇小鼠和20篇体外出版物。在临床研究中,这些药物对生存和转移性复发的作用尚不清楚。 22项临床前研究共同表明,几种抑制VGSC的药物可抑制癌症的扩散,迁移和侵袭。没有人参与,只有六项临床前研究直接调查了药物对VGSC活性的影响。由于缺乏标准化的方法和结果指标,研究难以进行比较。我们得出结论,VGSC抑制剂的益处需要进一步研究。未来研究和结果测量的标准化应能使研究有意义地进行比较。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号